Friday 6 November 2026 Export BMRN’s income statement to Excel — free account

BioMarin Pharmaceutical Inc.

BioMarin Pharmaceutical Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3.2 billion, up 12.9% from fiscal 2024.

Revenue: +32.0%
EPS: −296.6%
Free cash flow: −52.3%
Total debt: +599.5%

Quarter to September 2026, against a year earlier

Revenue growth 3 yrs

55.56 0.56 −1.00%

Follow BMRN

Alert me

Market cap: $10.9B
P/E: 0.0×
Fwd P/E: 32.7×
Dividend yield: —
F-score: 5/9
Altman Z: 5.67
Beneish M: −2.49
Dividend safety: n/a

Overview Business Profile Earnings & Analysis Segments Valuation Filings

BioMarin Pharmaceutical Inc. (BMRN) revenue by segment, product and region

Where the money comes from and where it goes

Fiscal 2025: revenue by segment, and margins
Reportable Segment	3,221	100.00%
Gross margin		77.73%
Operating margin		12.71%
Pre-tax margin		14.98%

Revenue by product or service $m

Line	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016
VOXZOGO	927 28.78%	735 25.76%	470 19.42%	169 8.07%	6 0.32%	—	—	—	—	—
VIMIZIM	792 24.59%	740 25.92%	701 28.98%	664 31.67%	623 33.75%	—	—	—	—	—
NAGLAZYME	485 15.07%	480 16.80%	420 17.37%	444 21.17%	380 20.61%	—	—	—	—	—
PALYNZIQ	433 13.45%	355 12.44%	304 12.56%	255 12.17%	237 12.86%	—	—	—	—	—
ALDURAZYME	209 6.47%	184 6.44%	131 5.43%	128 6.13%	123 6.65%	—	—	—	—	—
BRINEURA	186 5.79%	169 5.92%	162 6.69%	154 7.36%	128 6.93%	—	—	—	—	—
KUVAN	100 3.09%	121 4.24%	181 7.47%	228 10.86%	286 15.48%	—	—	—	—	—
Royalty and other revenues	53 1.66%	44 1.56%	47 1.93%	54 2.58%	63 3.40%	55 2.93%	43 2.52%	21 1.40%	43 3.29%	6 0.58%
ROCTAVIAN	36 1.11%	26 0.91%	3 0.14%	0 0.00%	0 0.00%	—	—	—	—	—
Product Four	—	—	—	—	—	—	—	—	413 31.46%	354 31.70%
Product Three	—	—	—	—	—	—	—	—	408 31.02%	348 31.16%
Product Two	—	—	—	—	—	—	—	—	332 25.29%	297 26.55%
Product One	—	—	—	—	—	—	—	—	90 6.85%	94 8.39%
Product Five	—	—	—	—	—	—	—	—	19 1.44%	18 1.61%
Product Six	—	—	—	—	—	—	—	—	9 0.65%	0 0.00%
Product Seven	—	—	—	—	—	—	—	—	0 0.00%	0 0.00%
Enzyme Product	—	—	—	—	1,492	—	—	—	—	—
Net product revenues	3,168	2,809	2,373	2,042	1,783	—	—	—	1,270	1,110
Revenue	3,221	2,854	2,419	2,096	1,846	1,860	1,704	1,491	1,314	1,117

Revenue by segment $m

Line	FY2025	FY2024	FY2023	FY2022
Reportable Segment	3,221 100.00%	2,854 100.00%	2,419 100.00%	2,096 100.00%
Revenue	3,221	2,854	2,419	2,096

Gross profit by segment $m, and margin

	FY2025	FY2024	FY2023	FY2022
Reportable Segment	‡	‡	‡	‡
Gross profit	‡	‡	‡	‡
	‡	‡	‡	‡
	‡	‡	‡	‡
	‡	‡	‡	‡
	‡	‡	‡	‡
	‡	‡	‡	‡
	‡	‡	‡	‡
	‡	‡	‡	‡
	‡	‡	‡	‡
	‡	‡	‡	‡
	‡	‡	‡	‡

Revenue by region $m

Line	FY2020	FY2019	FY2018	FY2017	FY2016	FY2015	FY2014	FY2013	FY2012
United States	912 49.04%	778 45.68%	697 46.73%	588 44.78%	508 45.44%	444 49.90%	384 51.22%	284 51.83%	250 49.88%
Europe	518 27.87%	509 29.88%	436 29.27%	399 30.36%	341 30.51%	171 19.24%	136 18.18%	116 21.10%	110 21.94%
Rest Of World	224 12.03%	198 11.60%	173 11.60%	145 11.01%	121 10.84%	132 14.87%	111 14.77%	81 14.79%	67 13.33%
Latin America	206 11.07%	219 12.84%	185 12.41%	182 13.85%	147 13.20%	142 15.99%	119 15.82%	67 12.28%	74 14.86%
Revenue	1,860	1,704	1,491	1,314	1,117	890	749	548	501

Operating figures as reported in each quarter’s results release or filing

Figure	Quarter	Latest	A year before	Change
Children being treated with VOXZOGO, year-over-year growth	Q3 FY2026	17.0%	—	—
Countries with children treated with VOXZOGO	Q3 FY2026	58.00	55.00	+5.45%

	Q3 FY2026	Q2 FY2026	Q1 FY2026	Q3 FY2025	Q2 FY2025	Q1 FY2025
Children being treated with VOXZOGO, year-over-year growth	‡	‡	‡	‡	‡	‡
Countries with children treated with VOXZOGO	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡

As each company reports them in its 10-K and 10-Q filings, in US dollars. Where a later filing recast a year's segments, the year is shown as recast; a period whose breakdown does not add up to the company's revenue is left out.